pubmed-article:18458054 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0024432 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C1414691 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:18458054 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:18458054 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:18458054 | pubmed:dateCreated | 2008-7-23 | lld:pubmed |
pubmed-article:18458054 | pubmed:abstractText | Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor alpha (TNF-alpha) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-alpha in a dose- and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca(2+), production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-alpha production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands ( Mol Pharmacol 68: 1301-1310, 2005 ). Overall, these compounds represent novel FPRL1 agonists that induce TNF-alpha, a response distinct from those induced by other known FPR and FPRL1 agonists. | lld:pubmed |
pubmed-article:18458054 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:language | eng | lld:pubmed |
pubmed-article:18458054 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18458054 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18458054 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18458054 | pubmed:month | Aug | lld:pubmed |
pubmed-article:18458054 | pubmed:issn | 1521-0111 | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:QuinnMark TMT | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:TianJunJ | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:YeRichard DRD | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:SchepetkinIgo... | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:KhlebnikovAnd... | lld:pubmed |
pubmed-article:18458054 | pubmed:author | pubmed-author:KirpotinaLili... | lld:pubmed |
pubmed-article:18458054 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18458054 | pubmed:volume | 74 | lld:pubmed |
pubmed-article:18458054 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18458054 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18458054 | pubmed:pagination | 392-402 | lld:pubmed |
pubmed-article:18458054 | pubmed:dateRevised | 2011-1-7 | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:meshHeading | pubmed-meshheading:18458054... | lld:pubmed |
pubmed-article:18458054 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18458054 | pubmed:articleTitle | Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production. | lld:pubmed |
pubmed-article:18458054 | pubmed:affiliation | Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA. | lld:pubmed |
pubmed-article:18458054 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18458054 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:18458054 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
pubmed-article:18458054 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:18458054 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18458054 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18458054 | lld:pubmed |